T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex ...

Oncolytic adenoviruses were designed to reach potent intratumoral T-cell activation via expression of bifunctional-T-cell ...

A bispecific antibody (BsAb) is a type of artificial protein with the ability to bind to two distinct antigens or two epitopes of one antigen at the same time. Bispecific antibodies can assume a ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

“We believe that the combination of Medigene’s 3S TCR and WuXi Biologics’ CD3 mAb and bispecific platform offers the potential of a best ... Medigene AG is an immuno-oncology platform company ...

Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG ...

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with ...

Chimeric antigen receptor (CAR) T-cell therapy has had ... The novel bispecific T-cell engager (BiTE) binds DLL3 on cancer ...

QLS32015, a novel humanized IgG1 T-cell retargeting bispecific antibody, targets both GPRC5D, a G protein-coupled receptor ...